[Adult onset Still's disease and lymphoma: a rare association]. / Maladie de Still de l'adulte et lymphome: une association rare.

Adult onset Still's disease (AOSD) and lymphomas are diseases characterized by very similar clinical and histopathological manifestations. The association between these diseases has rarely been reported in the literature. We here report the case of a 26-year old patient diagnosed with adult onset Still's disease. She had been previously treated for large B-cell Non-Hodgkin lymphoma (LBCNHL) with chemotherapy and haemopoietic stem-cell autograft with complete remission. The association between AOSD and lymphoma is rare and in all cases AOSD has been diagnosed before lymphoma. The peculiarity of this study lies in the succession LBCNHL- AOSD and raises several hypotheses on the association between these two diseases. The association between non-autoimmune diseases and lymphoid hemopathies have been widely demonstrated, whether it is the progression of autoimmune diseases vs lymphoma or non-autoimmune disease manifestations occurring in patients with this disease. This study highlights the difficult distinction between these diseases.

[Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease]. / Les antagonistes de l'interleukine-6 (tocilizumab) dans la maladie de still réfractaire de l'adulte.

INTRODUCTION: The pathogenesis of Still's disease is best elucidated for the better recognition of the involvement of Many pro-inflammatory cytokines in the genesis of this condition. Publications have reported the contribution beneficial for certain biotherapeutics, such as anti-TNFa, the anti-CD20 or antagonists of interleukine1 (IL-1) tested successfully in the treatment of systemic Juvenile idiopathic arthritis (Still's disease the child), the tocilizumab is a humanized monoclonal antibody directed against the receptor for interleukin-6 and is beginning to be reported as effective in some refractory cases of Still's disease in adults. PATIENTS: We report two young patients with Still's disease in adults with refractory early and prolonged remission after the first infusion tocilizumab. CONCLUSION: The tocilizumab can be used in patients MSA with refractory after failure or intolerance conventional treatments.